

21120.9204 Client Specific SARS-CoV-2 RT-PCR Performance 9.0

# 21120.9204 Client Specific SARS-CoV-2 RT-PCR Performance

# Copy of version 9.0 (approved and current)

Last Approval or **Periodic Review Completed** 

05-Oct-2020

**Uncontrolled Copy** printed on 04-Nov-2020 17:00

**Next Periodic Review Needed On or Before** 

05-Oct-2021

**Printed By** 

(b) (6)

**Effective Date** 

05-Oct-2020

Organization ViraCor

## Comments for version 9.0

Add in reagent section a sentence to check lot numbers and expiration dates of all reagents. In reponse to CA-00315

## **Approval and Periodic Review Signatures**

Туре	Description	Date	Version	Performed By	Notes
Approval	(b) (6)	05-Oct-2020 20:29	9.0	(b) (6)	
Approval	(b) (6) Approval	05-Oct-2020 15:17	9.0	(b) (6)	
Approval	(b) (6)	07-Sep-2020 20:27	8.0	(b) (6)	
Approval	(b) (6) Approval	01-Sep-2020 14:17	8.0	(b) (6)	

(b) (6) 10-Aug-2020 8:54 7.0 Approval (b) (6) (b) (6) Approval 05-Aug-2020 Approval 7.0 (b) (6) 16:25 27-Jul-2020 9:41 6.0 (b) (6) Approval (b) (6) (b) (6) Approval 26-Jul-2020 11:31 6.0 (b) (6) Approval (b) (6) 06-Jul-2020 20:31 5.0 Approval (b) (6) (b) (6) Approval (b) (6) 02-Jul-2020 8:43 5.0 Approval 15-Jun-2020 12:52 (b) (6) Approval (b) (6) (b) (6) 12-Jun-2020 9:28 4.0 (b) (6) Approval Approval (b) (6) 04-Jun-2020 10:53 3.0 Approval (b) (6) (b) (6) 04-Jun-2020 10:35 Approval 3.0 (b) (6) Approval

Approval (b) (6)

03-Jun-2020 14:39 2.0

(b) (6)

Approval

(b) (6) Approval

03-Jun-2020 14:28 2.0 (b) (6)

Approval

(b) (6)

25-May-2020 20:26

1.0

(b) (6)

Approval

22-May-2020 13:00

1.0

(b) (6)

# **Version History**

Version	Status	Туре	Date Added	Date Effective	Date Retired
9.0	Approved and Current	Major revision	05-Oct-2020	05-Oct-2020	Indefinite
8.0	Retired	Major revision	01-Sep-2020	07-Sep-2020	05-Oct-2020
7.0	Retired	Major revision	05-Aug-2020	17-Aug-2020	07-Sep-2020
6.0	Retired	Major revision	26-Jul-2020	03-Aug-2020	17-Aug-2020
5.2	Retired	Minor revision	20-Jul-2020	20-Jul-2020	03-Aug-2020
5.1	Retired	Minor revision	20-Jul-2020	20-Jul-2020	20-Jul-2020
5.0	Retired	Major revision	01-Jul-2020	06-Jul-2020	20-Jul-2020
4.0	Retired	Major revision	11-Jun-2020	15-Jun-2020	06-Jul-2020
3.0	Retired	Major revision	04-Jun-2020	04-Jun-2020	15-Jun-2020
2.0	Retired	Major revision	03-Jun-2020	03-Jun-2020	04-Jun-2020
1.0	Retired	Initial version	22-May-2020	25-May-2020	03-Jun-2020

# **Table of Contents**

INTENDED USE	2
METHOD PRINCIPLE	3
SPECIMEN REQUIREMENTS	3
Patient Preparation	3
Specimen Collection and Transport	3
Specimen Type and Handling	3
REAGENTS AND MATERIALS	
(b) (4) AND STANDARDS	5
QUALITY CONTROL	
EQUIPMENT AND SUPPLIES	
PROCEDURE	<u>c</u>
CALCULATIONS	14
RESULT REPORTING AND REPEAT CRITERIA	14
EXPECTED VALUES AND REFERENCE RANGES	
CLINICAL SIGNIFICANCE	21
PROCEDURE NOTES	22
PROCEDURE NOTES	22
PERFORMANCE SPECIFICATIONS	23
SAFETY	
RELATED DOCUMENTS	
REFERENCES	2
ATTACLINATAITC	2/

#### **INTENDED USE**

The Viracor SARS-CoV-2 assay is a real-time RT-PCR test intended for the qualitative detection of SARS-CoV-2 viral RNA in nasopharyngeal swabs, nasal swab, nasopharyngeal wash, nasal wash, oropharyngeal swab and bronchoalveolar lavage and for the quantitative detection of SARS-CoV-2 viral RNA in nasopharyngeal swabs, serum, plasma and saliva from individuals suspected of COVID-19. Testing is limited to Viracor Eurofins Clinical Diagnostics which is a Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a certified high-complexity laboratory.

Results are for the detection and identification of SARS-CoV-2 viral RNA. SARS-CoV-2 RNA is generally detectable in respiratory specimens during the acute phase of infection. Positive results are indicative of the presence of SARS-CoV-2 RNA. Clinical correlation with patient history and other diagnostic information is necessary to determine patient infection status. Positive results do not rule out bacterial infection or co-infection with other viruses. The agent detected may not be the definite cause of disease.

Laboratories within the United States and its territories are required to report all positive results to the appropriate public health authorities.

Negative results do not preclude SARS-CoV-2 infection and should not be used as the sole basis for patient management decisions. Negative results must be combined with clinical observations, patient history, and epidemiological information.

The qualitative assay is intended for use under the Food and Drug Administration's Emergency Use Authorization.

## **TEST INFORMATION**

Test Available: Qualitative: 13 Mar 2020, Quantitative: 26 May 2020

TAT: (b) (4)

The qualitative Coronavirus SARS-CoV-2 RT-PCR assay is a laboratory developed test involving nucleic acid extraction from respiratory (BAL, Nasal Wash, Nasal Swab, NP Swab, NP Wash, OP Swab) followed by real-time PCR amplification for the detection and quantification of SARS-CoV-2 genomic RNA. The quantitative Coronavirus SARS-CoV-2 RT-PCR assay is a laboratory developed test involving nucleic acid extraction from saliva, NP swab, serum and plasma.

**Department**: Infectious Disease - Biopharma

Test Code	Test Name	Specimen Type	
8398003A	Coronavirus SARS-CoV-2 RT-PCR (Study Quantitative)	Nasal Swab, NP Swab,	
8398006A	NR-Coronavirus SARS-CoV-2 RT-qPCR Study Quantitative	Saliva	
8398001A	Coronavirus SARS-CoV-2 RT-PCR (Study Qual with Ct analyte)		
8398002A	Coronavirus SARS-CoV-2 RT-PCR (Study Qualitative)	Novel Court ND Court	
8398004A	STAT Coronavirus SARS-CoV-2 RT-PCR (Study Qualitative)  Nasal Swab, NP Swab		
8398005A	AFTER HOURS Coronavirus SARS-CoV-2 RT-PCR (Study Qualitative)		
8398007A	Coronavirus SARS-CoV-2 RT-PCR Saliva (Study Qualitative)	Saliva	
8398009A	Coronavirus SARS-CoV-2 RT-PCR Serum (Study Quantitative)	Serum	
8398008A	Coronavirus SARS-CoV-2 RT-PCR Plasma (Study Quantitative)	Plasma	

#### Instrument Platforms:

Extraction:

21120.705 NucliSENS easyMAG (b) (4) Total Nucleic Acid Extraction

O NucliSENS easyMAG or (b) (4) utilizing(b) (4) protocol – Respiratory

21120.9152 (b) (4) Viral Pathogen Nucleic Acid Isolation

O ThermoFisher KingFisher utilizing (b) (4) protocol – Respiratory

• Amplification:

21120.461 Real-Time PCR and RT-qPCR Using (b) (4)

o (b) (4) utilizing (b) (4) (as listed in SOP 21120.696 PCR and RT-qPCR assay templates) for use with NucliSENS extraction

o (b) (4) utilizing (b) (4) (current template date)" (as listed in SOP 21120.696 PCR and RT-qPCR assay templates) for use with KingFisher extraction

#### METHOD PRINCIPLE

For all RT-PCR reactions using this procedure, nucleic acid extractions are performed using a bioMérieux NucliSENS easyMAG or (b) (4) instrument with (b) (4) or ThermoFisher KingFisher instrument with (b) (4) Viral/ Pathogen nucleic acid extraction reagents. The SARS-CoV-2 nucleic acid amplification assay is a real-time (b) (4) reverse-transcription polymerase chain reaction (RT-PCR) assay for detection and quantification of SARS-CoV-2 genomic RNA. Oligonucleotide primers are present which hybridize to the ssRNA genome and allow RNA amplification of a short region in the presence of thermostable DNA polymerase (Taq) enzyme and deoxy nucleotide triphosphates (dNTPs). A dual-labeled oligonucleotide probe that is complementary to an internal sequence of the amplification product is also present in the RT-PCR reaction mixture. The 5' exonucleolytic activity of Taq cleaves the fluorescent molecule (FAM) at the 5' end of the dual-labeled probe, thus releasing it from the effects of a fluorescence-quenching molecule (e.g. Black Hole Quencher 1) at the 3' end of the probe.

Additionally, oligonucleotide primers and a TaqMan probe for PCR detection of an internal extraction/ amplification control are also present in the SARS-CoV-2 RT-PCR reaction mix for the simultaneous detection of internal extraction/amplification control DNA in a multiplex reaction for each sample. Fluorescence intensity for both SARS-CoV-2 amplification and internal control amplification is measured in individual wells during each of the amplification cycles and a sample is considered positive when the signal intensity exceeds a predetermined baseline threshold value, which is used to establish a copies/mL value. The cycle number at which this occurs is referred to as the cycle threshold ( $C_T$ ). Detection of SARS-CoV-2 RNA in a sample is determined by the  $C_T$ .

## **SPECIMEN REQUIREMENTS**

## **Patient Preparation**

No special patient preparation is required for this assay.

## Specimen Collection and Transport


The performance of the quantitative SARS-CoV-2 assay was established using plasma, serum, saliva and nasopharyngeal swabs. (b) (4) are also considered acceptable specimen types for use with the SARS-CoV-2 assay but performance has not been established. See SOP 21120.435 Specimen Collection and Transport for procedures for collecting the proper specimens and how to prepare the specimens for transportation to the laboratory.

## Specimen Type and Handling

See SOP 21120.595 *Specimen Processing Guide* for specimen types accepted and specimen conditions required for each assay on Viracor Eurofins test menu. This includes clinical laboratory procedures involved in determining specimen acceptability for samples received for testing in the Clinical Laboratory.

See SOP 21120.596 *Clinical Laboratory Processing Guide* for procedure on accessing the electronic Specimen Processing Guide that details appropriate collection and transport containers, volume requirements, and responses for suboptimal specimen.

See SOP 21120.586 Specimen Receipt and Accessioning for procedures performed upon receipt of specimen. If the specimen is not going to be tested immediately then it should be stored according to temperatures listed in SOP 21120.600 Pre-processing Procedures for ID tests and Pre-processing Temperature Requirements for ID and AI.




#### **REAGENTS AND MATERIALS**

Check all reagent lot numbers and expiration dates prior to use. Lot numbers are tracked in accordance with SOP 21120.572 *Verification and Qualification of Critical Laboratory Materials*. Lots are used within kits only. Lot numbers are not used interchangeably without prior approval from vendor.

Extraction reagents can be found in the following SOPs:

- 21120.705 NucliSENS easyMAG (b) (4) Total Nucleic Acid Extraction
- 21120.9152 (b) (4) Viral Pathogen Nucleic Acid Isolation

Amplification reagents are as follows:



\*: See SOP 21120.380 Expiration Dating of Laboratory Materials for proper expiration dating assignment.

## Reagent Handling

Store reagents at temperature conditions listed above when not in use.

## Reagent Preparation

Assay specific primers and probes are prepared following SOP 21120.764 Oligonucleotide Mix Preparation and Quality Control Procedure.

# (b) (4) AND STANDARDS

Refer to SOP 21120.369 *Analytical Quality Control: Assay* (b) (4) *Verification* for instructions and guidelines for maintaining the analytical accuracy of laboratory test methods through regular calibration and calibration verification procedures.

## (b) (4)

Description	Source	Part/Cat No Storage / Expiration*
(b) (4) indicated in document SOP 21120.556 Acceptable Assay Standard Values	(b)	(4)

<sup>\*</sup> See SOP 21120.380 Expiration Dating of Laboratory Materials for proper expiration dating assignment.

#### Standards:

Description	Source	Part/Cat No	Storage / Expiration*
(b) (4) indicated in document 25 800xx Molecular RNA Start Set.	dard (b)	(4)	

<sup>\*</sup> See SOP 21120.380 Expiration Dating of Laboratory Materials for proper expiration dating assignment.

# (b) (4) and Standard Curve Preparation

Information regarding (b) (4) and Standard Curve Preparation can be found in SOP 21120.461 Real-Time PCR and RT-qPCR Using (b) (4) Instruments.


#### **QUALITY CONTROL**

The quality control program for this test is established in accordance with SOP 21120.517 *Analytical Quality Control: Quality Control Procedures*.

Quality control samples are prepared and control ranges are established and maintained in accordance with SOP 21120.517 *Analytical Quality Control: Quality Control Procedures*.


## **Extraction Controls**

Specimen Matrix	Description	Source	Part/Cat No.	Storage / Expiration*
All	MS2 Bacteriophage (Internal control)	(b) (4)		



<sup>\*</sup> See SOP 21120.380 Expiration Dating of Laboratory Materials for proper expiration dating assignment.

# **Amplification Controls**




<sup>\*</sup> See SOP 21120.380 Expiration Dating of Laboratory Materials for proper expiration dating assignment.

# **Control Procedure**

(b) (4)

(b) (4) indicated in SOP 21120.556 Acceptable Assay Standard Values) are included (b) (4) COV2 RT-PCR (b) (4)

(b) (4)





Quality Control Acceptance Criteria/Repeat Criteria

Refer to SOP 21120.578 *PCR and RT PCR Acceptance and Retest Criteria* for acceptance criteria and corrective actions for (b) (4) (b) (4)

# Acceptance Criteria/Repeat Criteria

## **Negative Controls**





Internal Control
MS2 (b) (4)
Acceptable Ct (b) (4)



## **Proficiency Testing**

These tests shall be challenged by in-house and/or external proficiency testing (b) (4)

## **EQUIPMENT AND SUPPLIES**

Equipment and Supplies required to perform this assay can be found in the following SOPs:

- 21120.705 NucliSENS easyMAG (b) (4) Total Nucleic Acid Extraction
- 21120.9152 (b) (4) Viral Pathogen Nucleic Acid Isolation
- 21120.461 Real-Time PCR and RT-qPCR Using (b) (4) Instruments

The following SOPs may be used to perform this assay:

• 21120.7445 (b) (4) Plate Sealer Operation Maintenance and Calibration

# Preventative Maintenance

Follow maintenance procedures for equipment as included in the following SOPs:

- 21120.812 Operation, Qualification and Maintenance of the NucliSENS easyMAG
- 21120.6763 Operation Qualification and Maintenance of the (b) (4)
- 21120.9034 KingFisher Flex System Operation, Maintenance, and Calibration
- 21120.785 (b) (4) Operation, Maintenance, and Calibration

## **Environmental Conditions**

See instrument manuals for environmental conditions required for operation of equipment.

## **PROCEDURE**

The essential steps to perform the Coronavirus SARS-CoV-2 RT-PCR assay on clinical respiratory include:

# Preprocessing for saliva samples ONLY:

(b) (4)

## **Pre-Analytical**

General sample handling and workflow is described in SOP 21120.765 Clinical Laboratory Workflow Requirements for Infectious Disease, Isotope, and Molecular Testing.

<u>Safety Note</u>: Samples should incubate in lysis buffer in the BSC for (b) (4) prior to loading on the easyMAG,(b) (4) or KingFisher.


## **Analytical**

Nucleic Acid Extractions are performed using the one of the following SOPs:


- 21120.705 NucliSENS easyMAG (b) (4) Total Nucleic Acid Extraction
- 21120.9152 (b) (4) Viral Pathogen Nucleic Acid Isolation

For Qualitative testing (CVID 8639, 8734, 8640 & 8642)

Prepare Extraction Run Map in (b) (4)




For CVID 8639, 8734, 8640, 8642 **ONLY** use the **(b) (4)** 




For Quantitative testing (CVID 8638, 8505, 8645, 8644, 8646, 8726, 9256)


Prepare Extraction Run Map in (b) (4)



For Quantitative testing (Serum & Plasma only)

Prepare Extraction Run Map in (b) (4)






Nucleic Acid Amplification is performed according to SOP 21120.461 *Real-Time PCR and RT-qPCR Using* (b) (4) *Instruments*. The following apply specifically to the SARS-CoV-2 RT-PCR assay:

For Qualitative testing (CVID 8639, 8734, 8640, & 8642)

**Prepare Extraction Map** 

Log into (b) (4)




FOR CVID 8639, 8640, 8642 and 8734 ONLY use the clinical laboratory PCR procedure including standards, primer/probe and controls.

For Qualitative testing (CVID 8640, 8642, 8639 & 8734)

Prepare Amplification Map Using (b) (4)


Log into (b) (4)



For Quantitative testing (CVID 8638, 8505, 8645, 8644, 8646, 8726)

Prepare Amplification Map in (b) (4)


Log into (b) (4)



For Quantitative testing (Plasma and Serum ONLY)


Prepare Amplification Map in (b) (4)

Log into (b) (4)




Nucleic acid from the easyMAG(b) (4) extraction protocol will be amplified using the (b) (4) is used for the (b) (4) amplification and analysis. Settings are as follows:

(b) (4)



• Nucleic acid from the (b) (4) extraction protocol will be amplified using the (b) (4) is used for the (b) (4) Fast amplification and analysis. Settings are as follows:




# **Post-Analytical**

Analysis is performed according to SOP 21120.461 Real-Time PCR and RT-qPCR Using (b) (4) Instruments and SOP 21120.575 Reporting Results for ID. The following apply specifically to the SARS-CoV-2 RT-PCR assay:

• (b) (4)

## **CALCULATIONS**

**Manual Calculations:** 



**RESULT REPORTING AND REPEAT CRITERIA** 

Resulting Procedure


Refer to SOP 21120.578 *PCR* and *RT-qPCR* Acceptance and Retest Criteria for details regarding acceptability and corrective action for sample results. Refer to SOP 21120.575 Reporting Results for ID for procedures for result exporting and reporting.


Resulting Procedure (CVID 8644, 8646, 8730, 8726,8645, 9256)



Analysis of Results for CVID (8644, 8646, 8730, 8726, 8645, 9256)

A. Analyzing results







For CVID 8505, 8646, <u>8644, 8646, 8730, 8726, 9256 only</u>


(b) 
$$(4)$$


Analysis of Results for CVID (8734, 8639, 9734, 8640, &8642)






Analysis of Results Plasma and Serum:





Resulting is performed automatically during export according to rules described in SOP 21120.1212 *Real Time PCR and RT-qPCR Result Calculation and Rounding*. The following apply specifically to the SARS-CoV-2 RT-PCR assay:



Jncontil


## Units of Measure:

Quantitative: Copies/mL

(b) (4)

LOD= Limit of Detection

Nasopharyngeal swab – Qual EUA	Copies/mL
LOD	73 copies/mL
(b) (4)	
Nasopharyngeal swab – Quant LDT	Copies/mL
(b) (4)	
Saliva- Quant/Qual LDT	Copies/mL



# Clinically Reportable Range:

Reportable ranges for the assay are listed in SOP 21120.577 Rounding and Reporting Rules for qPCR and RT-qPCR Assays.

Test Code	Test Name	Reportable Range
8398002A 8398004A 8398005A	Coronavirus SARS-CoV-2 RT-PCR (Study Qualitative)	(h) (1)
8398003A and 8398006A, 8398009A, 8398008A	Coronavirus SARS-CoV-2 RT-PCR (Study Quantitative)	(1) (4)
8398001A 8398007A	Coronavirus SARS-CoV-2 RT-PCR (Study Qualitative)	
	Coronavirus SARS Cov2 Saliva Study Qualitative	


# Comments:

In order to be accurate with Saliva reporting in collection devices, the following comments will need to be added

(b) (4) (b) (4)

When resulting please follow these steps:

(b) (4)



Comment for CVID <u>8644, 8646, 8730, 8726 only:</u>

(b) (4)

## **EXPECTED VALUES AND REFERENCE RANGES**

Expected Values: Not Detected

Alert Values and Critical Values: There are no Alert or Critical values currently associated with this assay.

## **CLINICAL SIGNIFICANCE**

Coronavirus SARS-CoV-2 RT-PCR test is intended for the qualitative detection of SARS-CoV-2.

The qualitative LOD of Viracor's SARS-CoV-2 RT-PCR EUA qualitative assay is 73 copies/mL for nasal wash, nasopharyngeal swab and BAL specimen types. The (b) (4) of Viracor's SARS-CoV-2 RT-qPCR LDT quantitative/qualitative assay is(b) (4) for nasopharyngeal swab saliva specimen types. The assay

(b) (4)

has demonstrated that 100% of known

SARS-CoV-2 strains will be accurately detected with this assay.

# (b) (4)

At the end of 2019, an outbreak of the virus initially referred to as 2019 novel Coronavirus, later identified as SARS-CoV-2, occurred in Wuhan, Hubei Province, China. A betacoronavirus, like MERS-CoV and SARS-CoV, the virus originates from bats. As of January 30, 2020, the International Health Regulations Emergency Committee of the World Health Organization declared a "public health emergency of international concern."

The disease caused by SARS-CoV-2 has been named coronavirus disease 2019, abbreviated as COVID-19. Main symptoms of the disease include fever, cough and shortness of breath. The CDC recommends reaching out to a physician if you develop symptoms and have been in close contact with a person known to have COVID-19; or if you have recently traveled from an area with widespread or ongoing community spread of COVID-19. The virus is spread via person-to-person contact through respiratory droplets produced when a person coughs or sneezes. The best preventative measures are to avoid close contact with people who are sick; avoid touching nose, eyes and mouth; cover a cough or sneeze with a tissue and discard immediately; and clean and disinfect frequently touched objects and surfaces using a household cleaning spray or wipe. Washing your hands with soap and water for at least 20 seconds frequently is one of the best preventative measures and hand sanitizer can be used when soap and water are not available.

#### **PROCEDURE NOTES**

#### Testing System Unavailable

Viracor Eurofins takes precautions to ensure that testing systems do not have prolonged outages by ensuring that we have redundant equipment for all of our testing platforms. Therefore, our backup plan for a system outage is always to run patient specimens on the redundant system for the impacted assay(s). In rare instances, both the primary and secondary platforms can be out of service. In these cases, we store specimens according to their individual storage requirements until such time as the testing system is back to operational status and testing may resume again. In extreme cases whereby an entire testing system is going to be completely down for an extended period of time of (b) (4) clients will be notified and alternative testing options, potentially at other facilities will be communicated to them where possible and at their discretion.

#### LIMITATIONS OF THE METHOD

RNA purified from clinical specimens may contain endogenous inhibitors of the PCR reaction that, if undetected, could lead to false negative results. To allow definitive identification of RNA samples containing PCR inhibitors, an internal control bacteriophage is added to each sample prior to RNA extraction. Real-time PCR amplification of the internal control target is performed in a multiplex reaction along with the Coronavirus SARS-CoV-2 RT-PCR dual gene target reaction. If inhibition is detected (CT><sup>(6)</sup> (4) the clinical samples are re-extracted and retested. If inhibition is detected after re-extraction and retesting, the result is reported as "See Comment\*\*" with a comment stating "Endogenous inhibition of PCR was detected in this sample; therefore the results for this test were not conclusive. Additional testing with a new sample is recommended. Other PCR tests ordered on this specimen may be partially inhibited. Interpret results with caution." RNA purified from clinical specimens may also have residual nuclease activity which could result in target RNA degradation and false negative results. Inclusion of the internal bacteriophage lambda control allows rapid, definitive identification of any samples with residual nuclease activity.

Pathogen genomic sequence mutations or polymorphisms could lead to false negative results if the base changes occurred at the critical 3' ends of the oligonucleotide primers or the 5' end of the TaqMan dual-labeled probe. The genomic target for the Coronavirus SARS-CoV-2 RT-PCR assay was specifically selected due to the (b) (4)

(b) (4)
(b) (4) Amplification curves of all PCR results are monitored by a laboratory scientist for (b) (4) which is an indication of (b) (4)

(b) (4)

#### PERFORMANCE SPECIFICATIONS

Refer to the following documents for performance specifications for the Coronavirus SARS-CoV-2 RT-PCR assay:

- 21120.8918 SARS-CoV-2 (COVID-19) RT-qPCR Validation Report
- 21120.9142 SARS CoV 2 RT qPCR Validation Report Alt Ext & Amp methods
- 21120.9249 SARS CoV 2 RT qPCR Swab and (b) (4) Saliva Validation Report

#### **SAFETY**

The following personal protective equipment will be applied as directed in currently effective Safety SOPs, including but not limited to, gloves, masks, lab coats, face shields and eye protection.

Personnel executing these procedures must be trained on effective Safety SOPs as listed in 21120.265 *Safety Program*.

See Material Safety Data Sheet (MSDS) manual for further details regarding all agents in the kit.

#### **RELATED DOCUMENTS**

21120.785 (b) (4)

21120.265 Safety Program 21120.369 Analytical Quality Control: Assay Calibration and Calibration Verification 21120.380 Expiration Dating of Laboratory Materials 21120.435 Specimen Collection and Transport 21120.461 Real-Time PCR and RT-qPCR Using (b) (4) Instruments 21120.517 Analytical Quality Control: Quality Control Procedures 21120.551 Quality Control Testing of the (b) (4) for Clinical Testing 21120.554 Real Time PCR and RT-qPCR Result Calculation and Rounding 21120.556 Acceptable Assay Standard Values 21120.572 Verification and Qualification of Critical Laboratory Materials 21120.575 Reporting Results for ID 21120.577 Rounding and Reporting Rules for qPCR and RT-qPCR Assays 21120.578 PCR and RT PCR Acceptance and Retest Criteria 21120.580 (b) (4) User Procedures 21120.595 Specimen Processing Guide 21120.596 Clinical Laboratory Processing Guide 21120.600 Pre-processing Procedures for ID tests and Pre-processing Temperature Requirements for ID and AI 21120.640 (b) (4) Processing Procedure 21120.696 PCR and RT-qPCR assay templates 21120.705 NucliSENS easyMAG (b) (4) Total Nucleic Acid Extraction

21120.765 Clinical Laboratory Workflow Requirements for Infectious Disease, Isotope, and Molecular Testing

Operation, Maintenance, and Calibration

21120.764 Oligonucleotide Mix Preparation and Quality Control Procedure

21120.812 Operation, Qualification and Maintenance of the NucliSENS easyMAG

21120.873 Operation, Maintenance, and Calibration of (b) (4)

21120.3629 (b) (4) RT-qPCR Master Mix Calculation Sheet

21120.6763 Operation Qualification and Maintenance of the (b) (4)

21120.7445 (b) (4) Plate Sealer Operation Maintenance and Calibration

21120.9034 KingFisher Flex System Operation, Maintenance, and Calibration

21120.9152 (b) (4) (b) (4) Viral Pathogen Nucleic Acid Isolation

21120.9166 (b) (4) COV2 Fast Master Mix Calculation Sheet

Molecular RNA Standard Set

21120.8918 SARS-CoV-2 (COVID-19) RT-qPCR Validation Report. Original EUA assay (a qualitative assay). 21120.9109 SARS CoV 2 RT qPCR NW NP SWAB BAL and SERUM (using easyMAG 0-5 mL input) Validation Report. Original EUA validation data analyzed and reported quantitatively.

21120.9142 SARS CoV 2 RT qPCR Validation Report Alt Ext & Amp methods. (Bridged to the original EUA new methods: (b) (4)

(b) (4)

ve Real 21120.9451 Qualification Protocol to Verify the Limit of Detection, (b) (4) with regards to the SARS Coronavirus 2 (SARS-CoV-2) Reverse Transcription Qualitative Real Time PCR assay in Saline and VTM Specimens

#### **REFERENCES**

None

#### **ATTACHMENTS**

None